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Background: Vaccine-induced antibodies to envelope proteins frequently cause HIV seroconversion in
uninfected recipients of HIV vaccine candidates and may thus have an impact on the vaccinee’s ability to
donate blood or acquire a life insurance policy.
Objective: To determine the occurrence of positive test results when commonly used HIV immunoassays
areused to screen sera ofHIV-uninfectedvolunteerswho received anadjuvantedHIV-1vaccine candidate
containing HIV-1 antigens p24, reverse transcriptase, Nef and p17.
Study design: Sera of 50 subjects who received this polyprotein vaccine in a single center in Belgium were
tested with 6 HIV screening assays and 1 confirmation test. All samples were drawn one year after the
administration of the first of two vaccine doses given with one month interval.
Results: Forty-five (90%) sera showed a positive test result in at least one of the 7 HIV tests used. The
positivity rates were 88% in the Elecsys HIV Combi assay, 74% in the ADVIA Centaur EHIV and 48% in the
PRISM HIV O Plus assay.
Conclusions: Interpretation of HIV test results is becoming increasingly complex with the growing num-
ber of volunteers participating in prophylactic HIV vaccine trials worldwide and the rising number of
viral antigens included in these vaccine candidates. The results of this study in recipients of a highly
immunogenic adjuvanted polyprotein HIV vaccine candidate devoid of envelope proteins, illustrate the
increasingneed for approaches that candiscriminateHIV infection-inducedantibodies fromthoseelicited
by a vaccine.
© 2011 Elsevier B.V. All rights reserved.
1. Background
Since 1987, more than 40,000 volunteers received human
immunodeficiency virus (HIV) vaccine candidates worldwide.1
Vaccine-induced seropositivity (VISP) is a common outcome of HIV
vaccine trials,2 mostly associated with vaccines containing enve-
lope inserts.2–6
Current HIV screening policy relies on highly sensitive enzyme
immunoassays detecting antibodies against different proteins,
most often p24, HIV-1 gp41 and HIV-2 gp36. Although 4th gener-
ation tests reduce the size of the diagnostic window by combining
HIV antibody and p24 antigen detection,7–10 many clinical lab-
oratories still use 3rd generation assays. Western blot or line
immunoassay (LIA) confirmation tests are also antibody-based,11,12
andmay therefore also turnpositive after receipt ofmulti-antigenic
HIV vaccine candidates.3
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Since the focus of HIV vaccine research has broadened from
neutralizing antibody-inducing approaches to T-cell-inducing vac-
cines, increasing numbers of volunteers are receiving vaccine
candidates containing compound HIV protein inserts. We were
recently confronted with positive HIV screening test results in
two uninfected recipients of a highly immunogenic HIV-1 vaccine
candidate, consisting of the fusion protein F4 (p24-reverse tran-
scriptase (RT)-Nef-p17) and theAS01B AdjuvantSystem.13 All study
participants were at low risk of acquiring HIV infection, screened
twicewith the 4th generation AxSYMHIV Ag/Ab Combo test before
immunization, and remained seronegative after receipt of the study
vaccine.
2. Objective
To determine the occurrence of VISP in commonly used HIV
immunoassays inHIV-uninfectedvolunteerswho received anadju-
vanted HIV-1 vaccine candidate containing p24, RT, Nef and p17.
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Table 1
Antibody and antigen detection profile of the HIV immunoassays.
Immunoassay Manufacturer Detection profilea
HIV-1 Ab HIV-2 Ab HIV Ag
Env Gag Pol Env
4th generation screening tests
AxSYM HIV Ag/Ab Combo Abbott gp41 gp36 p24
Murex HIV Ag/Ab Combination Abbott Envb Polc Envb p24
Elecsys HIV Combi Roche gp41 RT gp36 p24
3rd generation screening tests
AxSYM HIV 1/2 gO Abbott Envb p24 Envb
PRISM HIV O Plus Abbott Envb p24 Envb
ADVIA Centaur EHIV 1/O/2 Siemens gp41 p24 gp36
Confirmation test
INNO-LIA HIV I/II Score Innogenetics gp41, gp120 p17, p24 p31 gp36, gp105
a HIV antibodies (Ab) or antigens (Ag) detected by the immunoassays.
b Envelope antigen detected by the assay, not further specified.
c Polymerase antigen detected by the assay, not further specified.
3. Study design
Samples. Serum samples from the PRO HIV-005 trial
(NCT00434512), conducted at Ghent University and Hospital
(Belgium), were examined.13 180 healthy HIV-uninfected volun-
teers received one month apart two doses of an HIV-1 vaccine
candidate from GlaxoSmithKline Biologicals (Rixensart, Belgium),
containing 10, 30 or 90g of F4 (p24-RT-Nef-p17) recombinant
protein, adjuvanted with AS01B or reconstituted with water for
injection (WFI). Fifty sera, drawn one year after administration of
the first dose, were selected from the different dose groups based
on F4 antibody concentrations, to ensure a balanced representation
of low, medium and high antibody levels.
Assays. IgG antibody responses to F4, p24, p17 and RT were
assessed by validated in-house enzyme-linked immunosorbent
assays (ELISA).13 The 4th generation AxSYM HIV Ag/Ab Combo
test (Abbott Diagnostics, Germany) was used as a screening test
during the clinical trial.14 Serum samples were re-tested with
five additional HIV screening assays, selected based on their com-
mon use and detection properties (Table 1).15 The test panel
included two4th generation assays,MurexHIVAg/AbCombination
(Abbott)16 and Elecsys HIV Combi (Roche Diagnostics, Germany),17
and three 3rd generation assays, AxSYM HIV 1/2 gO, PRISM HIV O
Plus (Abbott)14,18 and ADVIA Centaur HIV 1/O/2 Enhanced (EHIV)
(Siemens Medical Solutions Diagnostics, Germany).19 For confir-
matory testing, all 50 samples were analyzed with the INNO-LIA
HIV I/II Score assay (Innogenetics, Belgium) (Table 1). Trained lab-
oratory personnel scored the reactivity pattern for each individual
antigen on a scale from “−” to “4+”, according to themanufacturer’s
instructions.12,20
Statistical analysis. For tests detecting antibodies to correspond-
ing antigens, the association between in-house ELISA antibody
concentration and commercial test results was measured using
Spearman correlation in PASW Statistics 18.
4. Results
Table 2 provides an overview of all test results. All 50 samples
scorednegative in theAxSYMandMurexassays. In thePRISMassay,
25 subjects (50%) tested negative and 24 (48%) scored positive. In
the ADVIA test, 37 samples (74%) showed reactivity. Significant
correlations (p<0.001) were observed between p24 antibody con-
centrations in the in-house ELISA and each of two commercial kits
able to detect p24 antibodies (PRISM and ADVIA, S =0.76 and 0.74,
respectively). In the Elecsys test 44 subjects (88%) were consid-
ered seropositive based on the presence of anti-RT antibodies. A
strong correlation (p<0.001) was observed between the Elecsys
results and the RT antibody concentrations in the in-house ELISA
(S =0.77).
None of the 50 samples fulfilled the criteria for a positive confir-
mation test, but 41 (82%) were scored as “indeterminate” (Table 2).
Antigen p17 induced the weakest antibody responses, in line with
the in-house p17 ELISA (p=0.004, S =0.40). For p17, 41 sam-
ples were scored negative, 5 “±” and 4 “1+”. Higher responses
were observed against p24, with only 8 negatives, 1 “±”, 5 “1+”,
16 “2+” and 20 “3+”. The p24 LIA scoring correlated significantly
(p<0.001) with the in-house ELISA p24, the PRISM and ADVIA
results (S =0.83, 0.69 and 0.74, respectively).
5. Discussion
One year after receipt of an immunogenic HIV-1 vaccine
containing no envelope proteins, 90% of the HIV-uninfected vac-
cinees scored positive in at least 1 out of 6 commonly used HIV
screening assays. The seronegative subjects originated from the
non-adjuvanted control groups in which the lowest antibody titers
were measured. The frequency of positive test results in this
study largely exceeds that observed in a previous study examin-
ing Env-based vaccines in which only 20.4% of the selected vaccine
recipients reacted on at least 1 of 6 HIV screening tests.3 It also
exceeds the VISP rate of 41.7% recently reported by the HIV Vac-
cine Trials Network2 and of 41% induced by adenovirus type 5
vectored gag(/pol/nef)vaccines.21 Ourdata therefore strengthen the
concern that recipients of immunogenic and increasingly complex
HIV vaccine candidates may be misclassified as HIV-infected with
the current screening assays.
Because of the absence of anti-envelope antibodies, none of our
participants displayed a positive HIV confirmation test. However,
82% showed indeterminate test results on INNO-LIA due to reactiv-
ity with p24 and, to a lesser extent, p17 antigen. This may trigger
unnecessary concern and repeated testing, or elicit the use of more
expensive techniques such as polymerase chain reaction (PCR) to
exclude true HIV infection. This is illustrated by the experience of
a study participant who recently underwent routine HIV testing
in the United States. A positive HIV screening test result was con-
firmed by reactivity to p65, p55 and p51 in one Western blot and
to gp40, p24 and p18 in another. The absence of reactivity towards
gp41, gp120 and gp160, together with a negative HIV PCR result,
suggests that gp40 reactivity was due to low test specificity. Future
vaccine candidates containing envelope protein(s) in addition to
F4 may induce anti-envelope antibodies, thereby further limiting
the usefulness and discriminatory capacity of current confirmation
tests.
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Table 2
Results of the HIV screening and confirmatory tests in 50 serum specimens from uninfected HIV vaccine recipients.
Immunoassay Positive result [n (%) of subjects] Negative result [n (%) of subjects] Indeterminate result [n (%) of subjects]
Single antibody detection tests
In-house anti-F4 ELISA 44 (88) 6 (12) 0
In-house anti-p24 ELISA 36 (72) 14 (28) 0
In-house anti-p17 ELISA 7 (14) 42 (84) 1 (2)
In-house anti-RT ELISA 33 (66) 17 (34) 0
4th generation screening tests
AxSYM HIV Ag/Ab Combo 0 50 (100) 0
Murex HIV Ag/Ab Combination 0 50 (100) 0
Elecsys HIV Combi 44 (88) 6 (12) 0
3rd generation screening tests
AxSYM HIV 1/2 gO 0 50 (100) 0
PRISM HIV O Plus 24 (48) 25 (50) 1 (2)
ADVIA Centaur EHIV 1/O/2 37 (74) 13 (26) 0
Confirmation test
INNO-LIA HIV I/II Score 0 9 (18) 41 (82)
HIV vaccine recipients may experience stigmatization or
discrimination in situations where an HIV test is determin-
ing important decisions, such as donating blood, obtaining a
life or health insurance, or for purposes of immigration or
employment.4,22,23 In Belgium, the PRISMHIVOPlus test is used for
the centralized screening of blood donors, in combination with HIV
nucleic acid testing (NAT) of pooled samples. A positive screening
test result, as observed in 48% of subjects in this study, will auto-
matically lead toexclusion fromblooddonation, irrespectiveofNAT
and confirmation test results. To avoid such situations, all study
participants received a letter explaining that future HIV testing can
give false positive results, and a certificate of trial participation con-
taining information for physicians on the content of the vaccine,
together with contact details of the investigator and the sponsor.
This and preceding studies clearly demonstrate that HIV test
manufacturers shouldprovide complete information about compo-
sition and antibody detection profile of their products. Laboratories
using these screening tools should bewell informed about qualities
and limitations thereof. Participants in prophylactic HIV vaccine
trials should be selected with care and they as well as their health
care providers need to be adequately informed about the vaccine
content and consequences of participation. Finally, this study high-
lights the need for the development of new testing strategies,24,25
allowing for a quick and reliable differentiation between vaccine-
induced immunity and true HIV infection.
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